Depomed changes name to Assertio Therapeutics
Shots:
- Depomed changes name to Assertio Therapeutics on Aug 15- 2018- with a strategic focus on our neurology- orphan and specialty medicines
- The rebranding is done after Senate committee opened probe for opioid marketing last year
- Assertio’s common stock has started trading with new ticker “ASRT” from Aug 15- 2018. Depomed also completed the relocation of headquarters from Newark to Lake Forest
Ref: Assertio Therapeutics| Image: Smarteranalyst
Click here to read the full press release
Tags
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com